Impact of the CCR5 gene polymorphism on the survival of metastatic melanoma patients receiving immunotherapy

Cancer Immunology, Immunotherapy

Volumn 57, Issue 5, 2008, Pages 685-691

  Ugurel, Selma ^a   Schrama, David ^a   Keller, Gunhild ^a   Schadendorf, Dirk ^b   Bröcker, Eva Bettina ^a   Houben, Roland ^a   Zapatka, Marc ^c   Fink, Wolfram ^b   Kaufman, Howard L ^d   Becker, Jürgen C ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d Columbia University Medical Center ^*  (United States)

Author keywords

CCR5; Immunotherapy; Melanoma; Polymorphism; Survival

Indexed keywords

CHEMOKINE RECEPTOR CCR5; RECOMBINANT ALPHA INTERFERON; RECOMBINANT GAMMA INTERFERON; RECOMBINANT INTERLEUKIN 2;

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER IMMUNOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CCR5 GENE; DISEASE COURSE; DNA EXTRACTION; FEMALE; FOLLOW UP; GENE DELETION; GENETIC POLYMORPHISM; GENOTYPE; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; MONOTHERAPY; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEX DIFFERENCE; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; FEMALE; HUMANS; IMMUNOTHERAPY; KAPLAN-MEIERS ESTIMATE; MALE; MELANOMA; MIDDLE AGED; POLYMORPHISM, GENETIC; RECEPTORS, CCR5; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 41549123803     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-007-0407-z     Document Type: Article

References (23)

1. Cyster JG (1999) Chemokines and cell migration in secondary lymphoid organs. Science 286:2098-2102
2. Murphy PM, Baggiolini M, Charo IF et al (2000) International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev 52:145-176
3. Dias S, Choy M, Rafii S (2001) The role of CXC chemokines in the regulation of tumor angiogenesis. Cancer Invest 19:732-738
4. Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420:860-867
5. Payne AS, Cornelius LA (2002) The role of chemokines in melanoma tumor growth and metastasis. J Invest Dermatol 118:915-922
6. Luboshits G, Shina S, Kaplan O et al (1999) Elevated expression of the CC chemokine regulated on activation, normal T cell expressed and secreted (RANTES) in advanced breast carcinoma. Cancer Res 59:4681-4687
7. Robinson SC, Scott KA, Wilson JL, Thompson RG, Proudfoot AE, Balkwill FR (2003) A chemokine receptor antagonist inhibits experimental breast tumor growth. Cancer Res 63:8360-8365
8. Mrowietz U, Schwenk U, Maune S et al (1999) The chemokine RANTES is secreted by human melanoma cells and is associated with enhanced tumour formation in nude mice. Br J Cancer 79:1025-1031
9. Lavergne E, Combadiere C, Iga M et al (2004) Intratumoral CC chemokine ligand 5 overexpression delays tumor growth and increases tumor cell infiltration. J Immunol 173:3755-3762
10. Yang X, Lu P, Fujii C et al (2006) Essential contribution of a chemokine, CCL3, and its receptor, CCR1, to hepatocellular carcinoma progression. Int J Cancer 118:1869-1876
11. Huang Y, Paxton WA, Wolinsky SM et al (1996) The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med 2:1240-1243
12. Galvani AP, Novembre J (2005) The evolutionary history of the CCR5-Delta32 HIV-resistance mutation. Microbes Infect 7:302-329
13. Martinson JJ, Chapman NH, Rees DC, Liu YT, Clegg JB (1997) Global distribution of the CCR5 gene 32-basepair deletion. Nat Genet 16:100-103
14. Galvani AP, Slatkin M (2003) Evaluating plague and smallpox as historical selective pressures for the CCR5-Delta 32 HIV-resistance allele. Proc Natl Acad Sci USA 100:15276-15279
15. Essner R, Lee HT, Itakura T, Huynh Y, Zogakis T, Morton DL (2005) Somatic gene mutations predict outcome of patients receiving adjuvant active specific immunotherapy after resection of stage IV melanoma. ASCO annual meeting 2005
16. Balch CM, Buzaid AC, Soong SJ et al (2001) Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19:3635-3648
17. Efron B (1977) The efficiency of Cox's likelihood function for censored data, 72 edn. pp 557-565
18. Therneau TM, Grambsch PM, Fleming TR (1990) Martingale-based residuals for survival models. Biometrika 77:147-160
19. Thurner B, Haendle I, Roder C et al (1999) Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 190:1669-1678
20. Schadendorf D, Ugurel S, Schuler-Thurner B et al (2006) Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Ann Oncol 17:563-570
21. Luiten RM, Kueter EW, Mooi W et al (2005) Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma patients. J Clin Oncol 23:8978-8991
22. Komenaka I, Hoerig H, Kaufman HL (2004) Immunotherapy for melanoma. Clin Dermatol 22:251-265
23. Essner R, Lee JH, Itakura H, Huynh Y, Scheri R, Morton D (2006) Chemokine receptor 5 (CCR5) {Delta}32 base pair somatic gene deletions from PBM predict survival of patients with advanced stage (IV) melanoma. J Clin Oncol (Meeting Abstracts) 24:10056